Cortexin
Also known as: Bovine brain peptide preparation
A standardised low-molecular-weight peptide preparation derived from bovine cerebral cortex, used in Russian clinical practice for cognitive impairment, post-stroke recovery, and traumatic brain injury research — the closest single sister to Cerebrolysin.
Cortexin is a licensed Russian bovine-brain peptide preparation used for CNS injury and cognitive impairment; parenteral (intramuscular) administration.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Neuroprotection
- Half-life
- Multi-component preparation with varied pharmacokinetics
Section 1
Overview
Cortexin is a complex peptide preparation produced by acetic-acid extraction and standardised processing of bovine cerebral cortex tissue. It contains a defined mixture of low-molecular-weight peptides (under 10 kDa) plus free amino acids, vitamins, and trace minerals. Mechanistically and historically it sits alongside Cerebrolysin as one of the two principal multi-component brain-derived peptide preparations used in Eastern European clinical practice.
The differences from Cerebrolysin are practical rather than fundamental. Cortexin is bovine-derived rather than porcine; it is administered intramuscularly rather than intravenously in most protocols; and its clinical positioning is broader, covering paediatric neurological indications (perinatal CNS injury, developmental delays) alongside the adult cognitive and stroke-recovery indications Cerebrolysin is best known for.
Like Cerebrolysin, its complexity is both a strength and a weakness in research terms. The multi-component preparation produces pleiotropic neurotrophic effects on multiple pathways simultaneously, which mirrors physiological neurotrophic signalling more closely than any single peptide; the same complexity makes the mechanism harder to dissect in clean experimental work.
Section 2
Discovery & History
- Developed in the Soviet Union in the late 1980s at the Herzen State Pedagogical University laboratories in Leningrad (later Geropharm), and registered as a medicinal product in Russia in 1999 following the licensed clinical evaluation programme.
- Standard prescription medication in Russia and several CIS countries for a range of cognitive, cerebrovascular, developmental, and paediatric neurological indications — one of the more commonly-prescribed neuropeptide preparations in the region.
- Subject to a substantial Russian-language clinical-trial body in stroke recovery, vascular dementia, traumatic brain injury, paediatric perinatal CNS injury, developmental delays, epilepsy, and post-encephalitic recovery.
- The preparation's approved paediatric indications are unusual for a peptide-based therapeutic — Cortexin has a broader paediatric clinical positioning than any other peptide preparation in this reference.
- Has not progressed to Western regulatory approval; remains unlicensed by the MHRA, EMA, and FDA. Import for clinical use is not permitted in the UK.
Section 3
Mechanism of Action
- 1Multi-component neurotrophic factor mimicry — the preparation contains fragments that reproduce aspects of BDNF, NGF, GDNF, and CNTF signalling at their cognate receptors without being any one of those molecules.
- 2Modulation of GABAergic and glutamatergic balance in cortical neurons — providing the mechanistic root for the anticonvulsant clinical positioning and the seizure-focus indications that Cerebrolysin does not share.
- 3Antioxidant effects via upregulation of endogenous antioxidant enzyme expression (superoxide dismutase, catalase, glutathione peroxidase) and direct radical scavenging by the low-molecular-weight peptide components.
- 4Anti-apoptotic effects in models of ischaemic and traumatic neuronal injury — preserved mitochondrial membrane potential, reduced caspase-3 activation, and improved neuronal survival following controlled insults.
- 5Modulation of microglial activation phenotype (M1/M2 balance shift) and measurable reduction of pro-inflammatory neuroinflammatory mediators (TNF-α, IL-1β, IL-6) in cerebral injury models.
- 6Neurogenic effects on adult hippocampal neurogenesis, contributing to the observed cognitive-recovery phenotype in post-stroke and paediatric CNS-injury indications.
- 7Modulation of cerebral vascular tone and cerebral blood flow parameters in some experimental models, extending the pharmacology into cerebrovascular applications.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Cognitive improvement in cerebrovascular disease and post-stroke populations in Russian clinical trials — MMSE and MoCA improvements over standard-of-care controls.
- 2Reported neuroprotective effects in traumatic-brain-injury research, including paediatric indications — the compound's most-differentiated clinical positioning.
- 3Anticonvulsant adjunct effects studied in epilepsy research and used clinically in Russian paediatric epilepsy protocols.
- 4Broad clinical use profile across paediatric and adult indications, providing extensive real-world experience unlike most peptide preparations.
- 5Long track record of post-marketing safety data in Russian and CIS clinical practice — several million patient-doses of pharmacovigilance data.
- 6Neurodevelopmental benefits in the Russian paediatric literature for perinatal hypoxic-ischaemic encephalopathy and developmental delays.
- 7Reported effects on speech-recovery post-stroke, extending the neuroprotective claim into functional-recovery endpoints.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Intramuscular injection (clinical use in approving jurisdictions) | Typical clinical doses 5–10 mg per injection | Daily during a treatment cycle | Cycles of 10 days, sometimes repeated after intervals |
Note: Not approved or prescribed in the UK; this information is for educational reference only.
Section 6
Administration Routes
- Intramuscular injection — the standard clinical route for the approved clinical use; typically administered as a single evening dose in a 10-day course.
- Intranasal administration has been explored in research and in some off-label protocols but is not the standard clinical route.
- Intravenous administration is used occasionally in acute-hospital settings for stroke and TBI protocols where rapid onset is prioritised.
- Oral administration is not used — the bioactive peptides are degraded by gastrointestinal proteases and would not survive first-pass metabolism in bioactive form.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in Russian clinical use across paediatric, adult, and elderly populations — the pharmacovigilance database is unusually robust for a peptide preparation.
- · Mild injection-site reactions reported in a minority of patients — local redness, transient tenderness, minor bruising at the injection site.
- · Occasional mild hypersensitivity reactions — local rash or urticaria; usually self-limiting.
- · Occasional transient headache during a course, particularly at initiation.
- · Rare reports of mild transient anxiety or agitation at higher doses, typically resolving with dose reduction.
Rare / theoretical
- · Anaphylactic reactions to the bovine-derived preparation, as with any animal-protein biologic — the SmPC in approving jurisdictions requires the availability of resuscitation equipment for the initial dose administration.
- · Theoretical considerations around prion or other transmissible-disease risk in animal-derived biologics — managed in approved manufacture by strict source-herd control, purification, and viral/prion inactivation validation.
- · Rare seizure-precipitation reports in specific patient populations, though the mechanism-of-action includes anticonvulsant effects — the paradox likely reflects individual susceptibility variability.
- · Theoretical interaction with immunosuppressant medications given the peptide preparation's immunomodulatory footprint — not documented in the clinical experience but a prudent consideration.
Contraindications
- · Not licensed in the UK — supply for human consumption is prohibited under the Human Medicines Regulations 2012.
- · Known hypersensitivity to bovine-derived proteins.
- · Pregnancy and lactation (per labelling in approving jurisdictions).
- · Active severe autoimmune disease — theoretical contraindication given the immunomodulatory footprint of the preparation.
Section 8
UK & EU Regulatory Context
United Kingdom
Not licensed as a medicine in the UK. Used clinically in the Russian Federation and several CIS countries.
European Union
Not approved by the EMA. No centralised EU authorisation; licensing status varies by member state.
Section 9
Clinical Studies Summary
Cortexin in post-stroke cognitive recovery
Russian multicentre randomised study in the post-stroke rehabilitation window (14-day intramuscular Cortexin course) reporting accelerated recovery of cognitive function (MMSE, MoCA), improved speech-recovery outcomes, and better activities-of-daily-living scores in patients receiving adjunct Cortexin during the rehabilitation phase versus standard care alone.
Read studyCortexin in paediatric perinatal CNS injury
Russian clinical research programme in neonates with hypoxic-ischaemic encephalopathy reporting improved neurodevelopmental outcomes (motor and cognitive milestones) at 1-year and 3-year follow-up in the Cortexin-treated group versus standard-care controls. Established the paediatric indication that differentiates Cortexin from other peptide preparations.
Comparative study of Cortexin and Cerebrolysin in vascular dementia
Russian comparative trial in vascular dementia populations reporting broadly similar cognitive outcomes between the two peptide preparations on standardised cognitive batteries (MMSE, ADAS-cog), with differences in tolerability profile (Cortexin fewer infusion-reactions given the IM route; Cerebrolysin more established Cochrane-level evidence).
Read studyCortexin in traumatic brain injury rehabilitation
Multi-site Russian trial in moderate-to-severe TBI populations reporting improved Glasgow Outcome Scale and cognitive-endpoint recovery in Cortexin-treated subjects versus standard-care controls at the 90-day rehabilitation follow-up.
Cortexin in paediatric epilepsy adjunct therapy
Russian paediatric neurology trial evaluating Cortexin as adjunct to standard-of-care antiepileptic therapy in cognitive-decline-associated childhood epilepsy, reporting improved cognitive scores and reduced seizure frequency in the treated cohort versus controls.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Cortexin for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Cortexin from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.